S0108 Bevacizumab in Treating Patients With Non-Hodgkin's Lymphoma

This study has been completed.

Study NCT00016094 Information provided by Southwest Oncology Group

First Received: May 6, 2001 Last Updated: January 11, 2012 History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Study Status:	This study has been completed.
Study Completion Date:	January 2008
Primary Completion Date:	December 2005 (Final data collection date for primary outcome measure)

Publications:

Stopeck AT, Unger JM, Rimsza LM, Bellamy WT, Iannone M, Persky DO, Leblanc M, Fisher RI, Miller TP. A phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin lymphoma: Southwest oncology group study S0108. Leuk Lymphoma. 2009 Apr 15;:1-8 [Epub ahead of print]

Stopeck AT, Bellamy W, Unger J, et al.: Phase II trial of single agent bevacizumab (Avastin) in patients with relapsed, aggressive non-Hodgkin's lymphoma (NHL): Southwest Oncology Group study S0108. [Abstract] J Clin Oncol 23 (Suppl 16): A-6592, 583s, 2005.